News
The IDC MarketScape report also states, "Docusign CLM is recognized for its user-friendly experience, strong security controls, and the ability to support collaboration and version control across the ...
DocuSign has undergone close to 20% correction from recent highs on concerns around growth saturation. Read why I think DOCU ...
Docusign (Nasdaq:DOCU), the Intelligent Agreement Management company, today unveiled new AI-powered tools-including AI ...
A number of stocks jumped in the afternoon session after the SaaS sector continued to rally as favorable inflation data bolstered hopes for a Federal Reserve interest rate cut. This optimism was ...
10d
Zacks Investment Research on MSNAdobe Drops 9% in a Month: Should You Buy the Dip in ADBE Stock?
Adobe ADBE shares have declined 9% in the past month. ADBE shares have plunged 25% year to date (YTD), underperforming the ...
StockStory.org on MSN11d
DocuSign (DOCU): Buy, Sell, or Hold Post Q1 Earnings?
DocuSign’s stock price has taken a beating over the past six months, shedding 21.1% of its value and falling to $69.33 per share. This might have investors contemplating their next move. Is there a ...
A mixed-use building in San Francisco's Jackson Square may hit the market again after its lender bought it at a foreclosure auction for $10 million.
Morgan Stanley's Mike Wilson thinks sectors like housing, commodities, and consumer goods could contain the biggest buying opportunity for investors.
Jim Cramer Says a Pullback After Marriott’s Earning is Usually a “Buying Opportunity” Published on August 6, 2025 at 10:18 pm by Syeda Seirut Javed in News ...
D-Wave stock slips as profitability remains elusive in its fiscal Q2. Here's the case for buying QBTS shares on the post-earnings decline.
Ethereum Treasury Stocks 'Better Buy' Than ETH ETFs, Standard Chartered Says The banks says ETH treasuries and ETH ETF holders each bought 1.6% of supply since June, with more upside ahead.
Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic fibrosis drug sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results